Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895”
We appreciate the opportunity to respond to the comment [...]
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/5/381 |
| _version_ | 1797600514919104512 |
|---|---|
| author | Daniel Rayson Sonal Gandhi Anil A. Joy Christine Brezden-Masley Karen A. Gelmon Sandeep Sehdev David Cescon Stephen Chia |
| author_facet | Daniel Rayson Sonal Gandhi Anil A. Joy Christine Brezden-Masley Karen A. Gelmon Sandeep Sehdev David Cescon Stephen Chia |
| author_sort | Daniel Rayson |
| collection | DOAJ |
| description | We appreciate the opportunity to respond to the comment [...] |
| first_indexed | 2024-03-11T03:50:16Z |
| format | Article |
| id | doaj.art-ec2922d259024378bc8588c63bddf687 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T03:50:16Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-ec2922d259024378bc8588c63bddf6872023-11-18T01:02:01ZengMDPI AGCurrent Oncology1198-00521718-77292023-05-013055050505310.3390/curroncol30050381Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895”Daniel Rayson0Sonal Gandhi1Anil A. Joy2Christine Brezden-Masley3Karen A. Gelmon4Sandeep Sehdev5David Cescon6Stephen Chia7Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, CanadaDivision of Medical Oncology/Hematology, Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDivision of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, CanadaDivision of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, CanadaDivision of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, CanadaDepartment of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, CanadaDepartment of Medical Oncology, University Health Network, Toronto, ON M5G 1Z5, CanadaDivision of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, CanadaWe appreciate the opportunity to respond to the comment [...]https://www.mdpi.com/1718-7729/30/5/381n/a |
| spellingShingle | Daniel Rayson Sonal Gandhi Anil A. Joy Christine Brezden-Masley Karen A. Gelmon Sandeep Sehdev David Cescon Stephen Chia Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895” Current Oncology n/a |
| title | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895” |
| title_full | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895” |
| title_fullStr | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895” |
| title_full_unstemmed | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895” |
| title_short | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895” |
| title_sort | reply to trudeau m fraser b the cadth pcodr expert review committee process explained comment on rayson et al access to neoadjuvant pertuzumab for her2 positive breast cancer in canada a dilemma increasingly difficult to explain i curr oncol i 2022 i 29 i 9891 9895 |
| topic | n/a |
| url | https://www.mdpi.com/1718-7729/30/5/381 |
| work_keys_str_mv | AT danielrayson replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 AT sonalgandhi replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 AT anilajoy replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 AT christinebrezdenmasley replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 AT karenagelmon replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 AT sandeepsehdev replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 AT davidcescon replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 AT stephenchia replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplainicurroncoli2022i29i98919895 |